StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Pacira BioSciences's enterprise value was $1.56B on Nov 11, 2026, against $1.14B a year earlier. Over the last 5 years it ranged from $289.84M to $2.76B, with a median of $1.20B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$1.56B+25.9%
2025Dec 31, 2025$1.24B+198.9%
2024Dec 31, 2024$415.62M-68.8%
2023Dec 29, 2023$1.33B-7.7%
2022Dec 30, 2022$1.44B-27.4%
2021Dec 31, 2021$1.99B-3.6%
2020Dec 31, 2020$2.06B+26.9%
2019Dec 31, 2019$1.62B+17.6%
2018Dec 31, 2018$1.38B-11.4%
2017Dec 29, 2017$1.56B+49.4%
2016Dec 30, 2016$1.04B-61.0%
2015Dec 31, 2015$2.67B-12.1%
2014Dec 31, 2014$3.04B+65.0%
2013Dec 31, 2013$1.84B+251.1%
2012Dec 31, 2012$525.46M+282.3%
2011Dec 30, 2011$137.44M–

More Pacira BioSciences figures

See a number that looks wrong?